September 1, 1996Circulation

Platelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina

View Full Paper

Ask AI

Bookmark

Why the study?

Does lamifiban infusion reduce the risk of death, nonfatal myocardial infarction, or urgent revascularization in patients with unstable angina?

Structured PICO

Does lamifiban infusion reduce the risk of death, nonfatal myocardial infarction, or urgent revascularization in patients with unstable angina?

Population

365 patients with unstable angina

Intervention

Lamifiban infusion (1, 2, 4, or 5 micrograms/min) for 72 to 120 hours, with concomitant aspirin (all patients) and heparin (28% of patients)

Comparator

Placebo infusion, with concomitant aspirin (all patients) and heparin (28% of patients)

Outcome

Composite of death, nonfatal myocardial infarction, or the need for an urgent revascularization during the infusion periodcomposite

In patients with unstable angina, the GP IIb/IIIa antagonist lamifiban reduced severe ischemic events during a 3- to 5-day infusion and at 1 month.

Authors

No takes yet. Share an insight, caveat, or question.

Supports lamifiban infusion in unstable angina; confirms GP IIb/IIIa antagonist benefit during the acute phase.

Roux et al. (1996) studied this question.

View Full Paper

Ask AI

Bookmark